Optimal actions in the maternal thyroid hormones (THs; 3,5,3'-triiodothyronine (T3) and thyroxine (T4)) during pregnancy are central to a normal fetal and neonatal consequence (Elbakry et al.
reported that about 90% of the endocrine malignancies are a thyroid cancer. A toxic nodular goiter (TNG) can increase the risk of metastatic follicular thyroid carcinoma (FTC) (Sahin et al., 2005 ). It appears that the prediction of metastatic follicular carcinoma does not fluctuate with the attendance or lacking hyperthyroidism (Tsuchiya et al., 1987; Paul and Sisson, 1990; Lin et al., 2004; Giovanella et al., 2010) . As well, Cakir et al. (2007) suggested that the prevalence of thyroid carcinoma was lower in subjects with Graves' disease than in subjects with toxic adenoma (TA) or toxic multi nodular goiter (TMG). Several investigators reported that Graves' disease (20-25%) is the utmost communal cause of hyperthyroidism and the frequency of thyroid nodules (Pacini et al., 1998; Kraimps et al., 2000; Taneri et al., 2005) . Indeed, cancer related to Graves' disease appears to be more destructive than those linked to multi nodular toxic goiter (MTG) or uni nodular toxic goiter (UTG) (Cappelli et al., 2006) . In addition, Wong et al. (2003) observed that thyrotoxicosis in women was associated with Hurthle cell carcinoma of the thyroid (a rare type of thyroid neoplasm).
More importantly, develop thyroid cancer in patients with Graves' and thyroid nodules were more severe than in patients with diffuse goiter ( Finally, it is worth pronouncing that maternal hyperthyroidism or thyrotoxicosis may increase the rate of development and progression of thyroid carcinoma and thyroid nodules. The disorders in the actions of the maternal thyroid gland (thyroid carcinoma or nodules) may disrupt the fetal and neonatal development and increase the possibility of mortality and morbidity. These disturbances may be depending on a family history of thyroid cancer, multiple endocrine neoplasia syndromes, a rapid growth of a nodule, and cervical lymphadenopathy. Thus, the incidence of a nodule in a hyper thyroidism or thyrotoxicosis should be carefully assessed to eliminate the attendance of malignancy. Additional studies are necessary to study the clinical and pathological features of materno fetal thyrotoxicosis and thyroid micro carcinoma (distinguish aggressive lesions from benign adenomas). It is important to study the prediction of non-metastatic hyperthyroidism with the follicular thyroid carcinoma. Additionally, every suspicious nodule related to hyperthyroidism should be appraised importantly. 
